Abstract: Objectives: To evaluate the efficacy and safety of the combination of Fructus Brucea Oil Emulsion and endocrine drugs for advanced prostate cancer. Methods: Databases including WanFang, CBM, CNKI, VIP, PubMed, EMBASE, and the Cochrane Library were systematically searched through inception to July 2014 to include the randomized controlled trials (RCTs) of fructus brucea oil emulsion plus endocrine drugs for advanced prostate cancer. Meta-analysis was performed using RevMan5.2 software. Results: A total of 7 RCTs involving 371 patients were analyzed. The results of meta-analysis indicated: ①there was statistical significant differences in improving KPS scores (OR=3.57, 95%CI: 2.24-5.67, P＜<0.00001). ②The change of the level of serum prostate specific antigen (PSA): There were no statistical significant differences in the change of the level of PSA after one month (MD=-3.49,95%CI: -15.03-8.05,P=0.55), three months (MD=-5.99,95%CI; -17.06-5.08,P=0.29), six months (MD=-3.25,95%CI: -16.89-10.38,P=0.64). ③The change of the level of serum testosterone: The change of the level of serum testosterone after one month (MD=1.92,95%CI: -0.10-3.74,P=0.04) have significant difference. The change of the level of serum testosterone after three months (MD=-0.09,95%CI: -1.83-1.65,P=0.92) and six months (MD=-0.15,95%CI: -1.85-1.55,P=0.86) have insignificant differences. ④Adverse events: there were no statistical significant differences in adverse events (MD=0.87,95%CI: 0.37-2.07,P=0.76). Conclusion: Fructus brucea oil Emulsion plus endocrine drugs has better efficacy, and the incidence of adverse events were similar in the treatment of advanced prostate cancer when compared to endocrine drugs alone.